Beth Woods
| Beth Woods | |
|---|---|
| Current and previous posts held | |
| 2017-present | Senior Research Fellow, Centre for Health Economics, University of York |
| 2014-2017 | Research Fellow, Centre for Health Economics, University of York |
| 2011-2013 | Director, Health Economics, Oxford Outcomes Ltd., Oxford |
| 2009-2011 | Senior Health Economist, Oxford Outcomes Ltd., Oxford |
| 2008-2009 | Health Economist, Oxford Outcomes Ltd., Oxford |
| 2006-2008 | Graduate Trainee, Oxford Outcomes Ltd., Oxford |
| Qualifications | |
| 2022-2024 | PhD entitled “Making better use of evidence to reflect heterogeneity and uncertainty in survival predictions within cost-effectiveness models” Department of Health Sciences, University of York. |
| 2006-2008 | MSc Economic Evaluation in Healthcare (Class Distinction) Department of Economics, City University, London |
| 2002-2005 | BA (Hons) Economics (Class 2.1) Faculty of Economics, Robinson College, University of Cambridge |
| Directorships and selected external roles | |
| 2021-current | Member of the Board of Directors for the York Health Economics Consortium |
| 2020-current | Member of the NIHR Health Technology Assessment Programme (HTA) Funding Committee |
| 2017-2019 | Member of the study Steering Committee for the NIHR HTA Project: 15/171/01 |
| 2016-present | Appointed member of Pharmacoeconomics Open editorial board. |
| Selected recent peer-reviewed publications |
Naci H, Murphy P, Woods B, Lomas J, Wei J, Papanicolas I. Population-health impact of new drugs recommended by the National Institute for Health and Care Excellence in England during 2000–20: a retrospective analysis. The Lancet. 2025 Jan 4;405(10472):50-60. Woods, B., Kearns, B., Schmitt, L., Jankovic, D., Rothery, C., Harnan, S., Hamilton, J., Scope, A., Ren, S., Bojke, L. and Wilcox, M., 2024. Assessing the Value of New Antimicrobials: Evaluations of Cefiderocol and Ceftazidime-Avibactam to Inform Delinked Payments by the NHS in England. Applied Health Economics and Health Policy. 2024 Nov 30:1-3. Woods B, Lomas J, Sculpher M, Weatherly HLA, Claxton KP. Achieving dynamic efficiency in pharmaceutical innovation: Identifying the optimal share of value and payments required. Health Economics. 2024 Apr;33(4):804-19. Faria R, Saramago P, Cox E, Weng S, Iyen B, Akyea RK, Humphries SE, Qureshi N, Woods B. How does cholesterol burden change the case for investing in familial hypercholesterolaemia? A cost-effectiveness analysis. Atherosclerosis. 2023 Feb 1;367:40-7. Woods B, Fox A, Sculpher M, Claxton K. Estimating the shares of the value of branded pharmaceuticals accruing to manufacturers and to patients served by health systems. Health Economics. 2021 Nov;30(11):2649-66. Woods B, Sideris E, Palmer S, Latimer N, Soares M. Partitioned Survival and State Transition Models for Healthcare Decision Making in Oncology: Where are we now? Value in Health. 2020 Dec 1;23(12):1613-1621. Woods B, Sideris E, Sydes MR, Gannon MR, Parmar MK, Alzouebi M, Attard G, Birtle AJ, Brock S, Cathomas R, Chakraborti PR. Addition of Docetaxel to First-line Long-term Hormone Therapy in Prostate Cancer (STAMPEDE): Modelling to Estimate Long-term Survival, Quality-adjusted Survival, and Cost-effectiveness. European Urology Oncology. 2018 Dec 1;1(6):449-58. Woods B, Rothery C, Anderson SJ, Eaton JW, Revill P, Hallett TB, Claxton K. Appraising the value of evidence generation activities: an HIV modelling study. BMJ Global health. 2018 Dec 1;3(6): e000488. |
| Selected recent grants | |
| 2024-2028 | Sculpher M, Wailoo A, Claxton K, Walker S, Griffin S, Longo F, Woods B, Soares M, Tsuchiya A, Rowen D, Keetharuth A, Hill H, Pudney S, Mukuria C. NIHR Policy Research Programme Policy Research Unit. PRP (PRU-02-02) Economic methods of Evaluation in Health & Care interventions. Sponsor: National Institute for Health Research (NIHR) Policy Research Programme Central Commissioning Facility, value: £5,499,958. |
| 2023-2028 | Qureshi N, Tata L, Bains M, Gomes M, Akyea R, Vinogradova Y, Llewellyn A, Priestley-Barnham L, Woods B, Kai J, Humphries S. Lipid-modifying therapy in children with familial hypercholesterolemia. Sponsor: National Institute for Health Research, value: £1,491,599. |
| 2020-2025 | PROFID: Implementation of personalised risk prediction and prevention of sudden cardiac death after myocardial infarction. Sponsor: European Commission, value: €19,884,569. |
| Selected invited seminars/presentations | |
| I have been an invited speaker at multiple academic institutions in the UK and internationally, at the World Bank in Washington, the World Health Organization in Geneva, and I am regularly invited to present at seminar series at the National Institute for Health and Care Excellence, NHS England, and the Department of Health and Social Care. | |